ILADS President Calls For More Comprehensive Dialogue To Prevent Chronic Lyme Disease During his closing remarks at the 2008 Scientific Meeting hosted by the International Lyme and Associated Diseases Society (ILADS), Dr. Daniel Cameron, ILADS president, stressed the need for more comprehensive dialogue between physicians and researchers regarding the prevention of chronic Lyme disease.
Source: www.medicalnewstoday.comBlack Women In Oklahoma Face More Obstacles To Early Prenatal Care Than White Women, Report Finds One in five black women in Oklahoma faces barriers to starting prenatal care, such as transportation problems, inability to obtain a doctor's appointment when wanted and not being able to begin prenatal treatment when wanted, according to an Oklahoma State Department of
Health report released on Tuesday, the
Source: www.medicalnewstoday.comThe Building Of The Blood-Brain Barrier Construction of the brain's border fence is supervised by Wnt/b-catenin signaling, report Liebner et al. in The Journal of Cell Biology. Like many a modern nation, the brain requires tight border security to maintain levels of nutrients and keep out toxic substances.
Source: www.medicalnewstoday.comUse Of Percutaneous Tibial Nerve Stimulation (PTNS) To Treat Overactive Bladder PHILADELPHIA, PA, USA (UroToday.com) - A retrospective chart review of 23 patients (22 women and 1 male) who completed 12 weekly, 20 minute treatments. Results showed a decrease in average number of daily UI episodes (78%), 14% decrease in nocturia and 29% in daytime frequency. Presented by 1L.S.
Source: www.medicalnewstoday.comNational Vaccine Information Center Says Government Denies Gardasil Risks The National Vaccine Information Center (NVIC) is calling on the Centers for Disease Control (CDC) and Food and Drug Administration (FDA) to publicly release the study design, data and names of principal investigators involved in a statement this week maintaining that Gardasil vaccine is safe with no serious side effects.
Source: www.medicalnewstoday.comOmrix Patient Enrollment Will Resume In Fibrin Pad U.S. Phase II Clinical Trial In Mild To Moderate Bleeding Omrix Biopharmaceuticals, Inc. ("Omrix") (NASDAQ: OMRI), a fully-integrated biopharmaceutical company that develops and markets biosurgical and immunotherapy products, announced today that the Fibrin Pad U.S. Phase II clinical trial in mild to moderate bleeding will resume patient enrollment and continue with no modifications. On October 9, 2008, the Company announced that the U.S.
Source: www.medicalnewstoday.comInspire Announces New Data From Denufosol Phase 3 Program At North American Cystic Fibrosis Conference Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today the presentation of additional data from TIGER-1, the Company's first Phase 3 trial with denufosol tetrasodium for the treatment of cystic fibrosis, at the 22nd Annual North American Cystic Fibrosis Conference (NACFC) in Orlando, FL on October 23 - 25, 2008.
Source: www.medicalnewstoday.comIncreasing Incidence Of Rheumatoid Arthritis In Women After four decades on the decline, rheumatoid arthritis is on the upswing among women in the United States. That's the finding presented by Mayo Clinic investigators at the annual meeting of the American College of Rheumatology/Association of Rheumatology
Health Professionals in San Francisco. "This is a significant finding and an indicator that more research needs to be done to better understand the causes and treatment of this devastating disease," says Sherine Gabriel, M.D.
Source: www.medicalnewstoday.comExploring Caffeine Intake In Women With OAB And Mental Health Disease PHILADELPHIA, PA, USA (UroToday.com) - Higher caffeine consumption can contribute to OAB. Many women who suffer from mental illness have OAB. The hypothesis was that women with mental heath disorders might self-medicate with caffeine.
Source: www.medicalnewstoday.comSie Foundation Launches Campaign To Expand Research By Government And Private Sector For Down Syndrome The Anna and John J. Sie Foundation today launched a major campaign to change the nation's approach to Down syndrome. The Foundation's goal is to significantly increase public and private research aimed at eradicating the ill effects associated with the chromosomal disorder and improve the
health outcomes for the 400,000 people in the United States, and millions worldwide, with the condition.
Source: www.medicalnewstoday.com
# posted by Network @ 9:00 AM
